Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
30
CASBF Quote, Financials, Valuation and Earnings
Last price:
$4.28
Seasonality move
:
19.62%
Day range:
$4.28 - $4.28
52-week range:
$3.20 - $6.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.87x
P/B ratio:
1.53x
Volume:
--
Avg. volume:
2K
1-year change:
3.69%
Market cap:
$1.1B
Revenue:
$116.2M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
$4.28 | -- | $1.1B | -- | $0.00 | 0% | 7.87x |
|
ADAG
Adagene, Inc.
|
$1.88 | $9.22 | $88.6M | -- | $0.00 | 0% | 846.10x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.80 | $4.00 | $16.4M | -- | $0.00 | 0% | 0.47x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.38 | -- | $4.5M | -- | $0.00 | 0% | 1.11x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.71 | $49.17 | $2B | -- | $0.00 | 0% | 4.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
22.42% | 0.328 | 12.26% | 2.94x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
$34M | $62K | -2.07% | -2.86% | 0.14% | -$2.1M |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
CanSino Biologics, Inc. vs. Competitors
-
Which has Higher Returns CASBF or ADAG?
Adagene, Inc. has a net margin of 9% compared to CanSino Biologics, Inc.'s net margin of --. CanSino Biologics, Inc.'s return on equity of -2.86% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.78.37% $0.02 $893M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About CASBF or ADAG?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 390.65%. Given that Adagene, Inc. has higher upside potential than CanSino Biologics, Inc., analysts believe Adagene, Inc. is more attractive than CanSino Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is CASBF or ADAG More Risky?
CanSino Biologics, Inc. has a beta of 1.527, which suggesting that the stock is 52.741% more volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CASBF or ADAG?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or ADAG?
CanSino Biologics, Inc. quarterly revenues are $43.3M, which are larger than Adagene, Inc. quarterly revenues of --. CanSino Biologics, Inc.'s net income of $3.9M is higher than Adagene, Inc.'s net income of --. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 7.87x versus 846.10x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.7.87x -- $43.3M $3.9M ADAGAdagene, Inc.846.10x -- -- --
-
Which has Higher Returns CASBF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of 9% compared to CanSino Biologics, Inc.'s net margin of -353.92%. CanSino Biologics, Inc.'s return on equity of -2.86% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.78.37% $0.02 $893M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About CASBF or CASI?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 399.81%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than CanSino Biologics, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than CanSino Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is CASBF or CASI More Risky?
CanSino Biologics, Inc. has a beta of 1.527, which suggesting that the stock is 52.741% more volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock CASBF or CASI?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or CASI?
CanSino Biologics, Inc. quarterly revenues are $43.3M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. CanSino Biologics, Inc.'s net income of $3.9M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 7.87x versus 0.47x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.7.87x -- $43.3M $3.9M CASICASI Pharmaceuticals, Inc.0.47x -- $3.1M -$10.9M
-
Which has Higher Returns CASBF or CPHI?
China Pharma Holdings, Inc. has a net margin of 9% compared to CanSino Biologics, Inc.'s net margin of -86.16%. CanSino Biologics, Inc.'s return on equity of -2.86% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.78.37% $0.02 $893M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About CASBF or CPHI?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CanSino Biologics, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe CanSino Biologics, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is CASBF or CPHI More Risky?
CanSino Biologics, Inc. has a beta of 1.527, which suggesting that the stock is 52.741% more volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock CASBF or CPHI?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or CPHI?
CanSino Biologics, Inc. quarterly revenues are $43.3M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. CanSino Biologics, Inc.'s net income of $3.9M is higher than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 7.87x versus 1.11x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.7.87x -- $43.3M $3.9M CPHIChina Pharma Holdings, Inc.1.11x -- $756.2K -$651.5K
-
Which has Higher Returns CASBF or SVA?
Sinovac Biotech Ltd. has a net margin of 9% compared to CanSino Biologics, Inc.'s net margin of --. CanSino Biologics, Inc.'s return on equity of -2.86% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.78.37% $0.02 $893M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CASBF or SVA?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CanSino Biologics, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe CanSino Biologics, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CASBF or SVA More Risky?
CanSino Biologics, Inc. has a beta of 1.527, which suggesting that the stock is 52.741% more volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock CASBF or SVA?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or SVA?
CanSino Biologics, Inc. quarterly revenues are $43.3M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. CanSino Biologics, Inc.'s net income of $3.9M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 7.87x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.7.87x -- $43.3M $3.9M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CASBF or ZLAB?
Zai Lab Ltd. has a net margin of 9% compared to CanSino Biologics, Inc.'s net margin of -30.98%. CanSino Biologics, Inc.'s return on equity of -2.86% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.78.37% $0.02 $893M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About CASBF or ZLAB?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 177.64%. Given that Zai Lab Ltd. has higher upside potential than CanSino Biologics, Inc., analysts believe Zai Lab Ltd. is more attractive than CanSino Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is CASBF or ZLAB More Risky?
CanSino Biologics, Inc. has a beta of 1.527, which suggesting that the stock is 52.741% more volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock CASBF or ZLAB?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or ZLAB?
CanSino Biologics, Inc. quarterly revenues are $43.3M, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. CanSino Biologics, Inc.'s net income of $3.9M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 7.87x versus 4.30x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.7.87x -- $43.3M $3.9M ZLABZai Lab Ltd.4.30x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 5.38% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 1.37% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is down 3.36% over the past day.
